Frontiers of Medicine
>> 2022,
Volume 16,
Issue 1
doi:
10.1007/s11684-021-0873-2
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Available online: 2022-02-25
Next
Previous
Abstract
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
京公网安备 11010502051620号
